Modification of Significant New Uses of Certain Chemical Substances (21-1.M)
EPA proposes to amend SNURs for certain chemical substances, potentially affecting chemicals used in med-spa products like disinfectants or solvents. Requires review of chemical inventory and compliance with new use restrictions.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa and aesthetics clinics using chemical substances covered by the proposed SNUR amendments. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due by November 14, 2022; compliance date upon final rule effective date (likely 2023).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA proposes to designate certain chemical substances as significant new uses, requiring notification before manufacturing or processing for those uses.
Who it affects
Med-spa and aesthetics clinics using chemical substances covered by the proposed SNUR amendments.
What you must do
Review chemical inventory to identify if any substances listed in the proposed rule are used; if so, prepare to submit a Significant New Use Notice (SNUN) before continuing those uses.
Deadline
Comments due by November 14, 2022; compliance date upon final rule effective date (likely 2023).
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication